
浏览全部资源
扫码关注微信
1.广州中医药大学 第一临床医学院,广州 510006
2.广州中医药大学 第一附属医院,广州 510004
张嘉骏,在读博士,从事鼻病的临床和实验研究,E-mail:zjjhero@qq.com
阮岩,博士,教授,主任医师,从事鼻病的临床和实验研究,E-mail:ruanyan63@163.com
收稿日期:2021-11-11,
网络出版日期:2022-02-21,
纸质出版日期:2022-07-20
移动端阅览
张嘉骏,贺雪成,刘沁东等.小青龙汤对变应性鼻炎小鼠IL-33/ST2信号通路的影响[J].中国实验方剂学杂志,2022,28(14):13-19.
ZHANG Jiajun,HE Xuecheng,LIU Qindong,et al.Effect of Xiao Qinglongtang on IL-33/ST2 Signaling Pathway in Mice with Allergic Rhinitis[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):13-19.
张嘉骏,贺雪成,刘沁东等.小青龙汤对变应性鼻炎小鼠IL-33/ST2信号通路的影响[J].中国实验方剂学杂志,2022,28(14):13-19. DOI: 10.13422/j.cnki.syfjx.20220806.
ZHANG Jiajun,HE Xuecheng,LIU Qindong,et al.Effect of Xiao Qinglongtang on IL-33/ST2 Signaling Pathway in Mice with Allergic Rhinitis[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):13-19. DOI: 10.13422/j.cnki.syfjx.20220806.
目的
2
探讨小青龙汤对鸡卵清白蛋白(OVA)诱导的变应性鼻炎(AR)小鼠的治疗作用及对白细胞介素-33(IL-33)/IL-1受体样2(ST2)信号通路的影响。
方法
2
72只雌性SPF级BALB/c小鼠随机分为正常组、模型组、氯雷他定组(2.05 mg·kg
-1
)、小青龙汤高、中、低剂量(20.02、10.01、5.005 g·kg
-1
)组。除正常组外,其余各组小鼠腹腔注射OVA溶液造成基础致敏,而后OVA溶液滴鼻激发致敏造成AR模型。每日局部滴鼻前30 min给药1次,正常组和模型组按20 mL·kg
-1
给与磷酸盐缓冲液(PBS),共7 d。记录末次OVA溶液滴鼻后10 min内小鼠打喷嚏和挠鼻的次数。给药7 d后收集血液,取小鼠鼻骨并脱钙制作病理切片。酶联免疫吸附测定法(ELISA)检测血清OVA特异性免疫球蛋白E(OVA-sIgE)、白细胞介素-4(IL-3)、白细胞介素-5(IL-4)、白细胞介素-13(IL-13)含量;苏木素-伊红(HE)染色观察鼻黏膜组织形态,糖原(PAS)染色观察鼻黏膜杯状细胞增生情况,吉姆萨(Giemsa)染色观察鼻黏膜嗜酸性粒细胞浸润情况;蛋白免疫印迹法(Western blot)检测鼻黏膜IL-33、ST2、IL-1受体辅助蛋白(IL-1RAP)蛋白表达水平。
结果
2
与正常组比较,模型组小鼠打喷嚏,挠鼻次数显著升高(
P
<
0.01),鼻黏膜水肿增厚,出现杯状细胞增生和嗜酸性粒细胞浸润,血清中OVA-sIgE、IL-4、IL-5、IL-13水平显著升高(
P
<
0.01),鼻黏膜组织IL-33、ST2、IL-1RAP蛋白表达均有明显升高(
P
<
0.05,
P
<
0.01)。给药后,与模型组比较,高剂量小青龙汤组小鼠打喷嚏,挠鼻次数降低(
P
<
0.01),鼻黏膜病理情况改善,血清中OVA-sIgE、IL-4、IL-5、IL-13水平降低(
P
<
0.01),鼻黏膜组织IL-33、ST2、IL-1RAP蛋白的表达均有明显下降(
P
<
0.05,
P
<
0.01)。
结论
2
小青龙汤对于OVA致敏AR小鼠有治疗作用,其作用可能与其调节IL-33/ST2信号通路及2型T辅助细胞(Th2)炎症因子,从而减轻Th2型免疫反应,缓解鼻黏膜损伤有关。
Objective
2
To investigate the therapeutic effect of Xiao Qinglongtang (XQLT) on ovalbumin (OVA)-induced allergic rhinitis (AR) in mice and its effect on the interleukin-33 (IL-33)/suppression of tumorigenicity 2 (ST2) signaling pathway.
Method
2
Seventy-two female BALB/c mice of SPF grade were randomly divided into a control group, a model group, a positive control group (loratadine, 2.05 mg·kg
-1
), and low-, medium-, and high-dose (5.005,10.01,20.02 g·kg
-1
) XQLT groups. All mice except for those in the control group were sensitized by intraperitoneal injection of OVA solution, and the AR model was induced by intranasal drops of OVA solution. Thirty minutes before local intranasal drops, drugs were administered once, and mice in the control group and the model group received phosphate buffered saline (PBS) at 20 mL·kg
-1
for 7 days. After the last intranasal drop of OVA solution, the times of sneezing and nasal rubbing of mice within 10 min was recorded. After drug administration for 7 days, blood samples were collected, and nasal bones of mice were decalcified for the preparation of pathological sections. The content of OVA-specific immunoglobulin E (OVA-sIgE), interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) was detected by enzyme-linked immunosorbent assay (ELISA) kits. Hematoxylin-eosin (HE) staining, periodic acid-Schiff (PAS) staining, and Giemsa staining were used to observe the pathological changes, goblet cell hyperplasia, and eosinophil infiltration of nasal mucosa, respectively. Western blot was used to detect the expression levels of IL-33, ST2, and IL-1 receptor accessory protein (IL-1RAP) in nasal mucosa.
Result
2
Compared with the control group, the model group showed increased times of sneezing and nasal rubbing (
P
<
0.01), edema and thickening of nasal mucosa, goblet cell hyperplasia and eosinophil infiltration, increased serum levels of OVA-sIgE, IL-4, IL-5 and IL-13 (
P
<
0.01), and increased protein expression of IL-33, ST2, and IL-1RAP in nasal mucosa (
P
<
0.05,
P
<
0.01). After drug administration, compared with the model group, the high-dose XQLT group showed reduced times of sneezing and nasal rubbing (
P
<
0.01), improved pathological conditions of nasal mucosa, reduced serum levels of OVA-sIgE, IL-4, IL-5, and IL-13 (
P
<
0.01), and declining protein expression of IL-33, ST2, and IL-1RAP in nasal mucosa (
P
<
0.05,
P
<
0.01).
Conclusion
2
XQLT has a therapeutic effect on OVA-sensitized AR mice, and the mechanism may be related to the regulation of the IL-33/ST2 signaling pathway and Th2 inflammatory cytokine to reduce Th2 inflammatory response and alleviate nasal mucosal injury.
BOUSQUET J , ANTO J M , BACHERT C , et al . Allergic rhinitis [J]. Nat Rev Dis Primers , 2020 , 6 ( 1 ): 95 .
INCORVAIA C , CAVALIERE C , FRATI F , et al . Allergic rhinitis [J]. J Biol Regul Homeost Agents , 2018 , 32 ( Suppl 1 ): 61 - 66 .
中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组 , 中华医学会耳鼻咽喉头颈外科学分会鼻科学组 . 中国变应性鼻炎诊断和治疗指南(2022年,修订版) [J]. 中华耳鼻咽喉头颈外科杂志 , 2022 , 57 ( 2 ): 106 - 129 .
DATTAGUPTA A , IMMANENI S . ST2: Current status [J]. Indian Heart J , 2018 , 70 ( Suppl 1 ): S96 - S101 .
ZHANG L , JIANG L L , CAO Z W . Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF- κ B signaling pathway [J]. Eur Rev Med Pharmacol Sci , 2017 , 21 ( 20 ): 4501 - 4508 .
DE GROVE K C , PROVOOST S , BRAUN H , et al . IL-33 signalling contributes to pollutant-induced allergic airway inflammation [J]. Clin Exp Allergy , 2018 , 48 ( 12 ): 1665 - 1675 .
ZOLTOWSKA NILSSON A M , LEI Y , ADNER M , et al . Mast cell-dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma [J]. Am J Physiol Lung Cell Mol Physiol , 2018 , 314 ( 3 ): L484 - L492 .
LI D , GUABIRABA R , BESNARD A G , et al . IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice [J]. J Allergy Clin Immunol , 2014 , 134 ( 6 ): 1422 - 1432.e11 .
KOTSIOU O S , GOURGOULIANIS K I , ZAROGIANNIS S G . IL-33/ST2 axis in organ fibrosis [J]. Front Immunol , 2018 , 9 : 2432 .
孟欣 , 张晓敏 , 戴启刚 , 等 . IL-33/ST2信号转导通路与过敏性鼻炎的研究进展 [J]. 中华中医药杂志 , 2015 , 30 ( 6 ): 2032 - 2035 .
LAM E P , KARIYAWASAM H H , RANA B M , et al . IL-25/IL-33-responsive Th2 cells characterize nasal polyps with a default Th17 signature in nasal mucosa [J]. J Allergy Clin Immunol , 2016 , 137 ( 5 ): 1514 - 1524 .
ZHENG R , CHEN Y , SHI J , et al . Combinatorial IL-17RB, ST2, and TSLPR signaling in dendritic cells of patients with allergic rhinitis [J]. Front Cell Dev Biol , 2020 , 8 : 207 .
谢慧 . 变应性鼻炎的中医治疗 [J]. 山东大学耳鼻喉眼学报 , 2016 , 30 ( 4 ): 22 - 25 .
刘静 . 基于整体观念变应性鼻炎的中医辨证论治 [J]. 山东大学耳鼻喉眼学报 , 2017 , 31 ( 3 ): 28 - 30 .
李鸣婧 , 张晓阳 . 变应性鼻炎中医临床辨证研究现状与思考 [J]. 中华中医药学刊 , 2012 , 30 ( 7 ): 1635 - 1637 .
忻耀杰 , 滕磊 , 魏慈芸 , 等 . 变应性鼻炎的中医诊疗心悟 [J]. 中国中西医结合耳鼻咽喉科杂志 , 2018 , 26 ( 3 ): 163 - 165 .
刘敏 , 程发峰 , 王庆国 , 等 . 基于六经辨证的变应性鼻炎诊治思路 [J]. 中华中医药杂志 , 2015 , 30 ( 1 ): 17 - 19 .
郭晓黎 , 任小宁 . 小青龙汤治疗肺气虚寒型变应性鼻炎27例临床观察 [J]. 云南中医中药杂志 , 2019 , 40 ( 5 ): 60 - 61 .
潘虹 . 小青龙汤治疗变应性鼻炎临床观察 [J]. 中医药临床杂志 , 2018 , 30 ( 7 ): 1326 - 1328 .
刘铮 , 阮岩 . 中医健康管理联合小青龙汤治疗儿童变应性鼻炎临床研究 [J]. 中华中医药杂志 , 2020 , 35 ( 4 ): 1846 - 1849 .
郑永艳 , 周园 , 周联 , 等 . 小青龙汤抗过敏作用及其机制研究 [J]. 时珍国医国药 , 2017 , 28 ( 5 ): 1052 - 1055 .
杨荣刚 , 阮岩 , 潘增烽 , 等 . 小青龙汤对变应性鼻炎小鼠胸腺基质促淋巴细胞生成素及Th2细胞因子的影响 [J]. 辽宁中医杂志 , 2018 , 45 ( 8 ): 1758 - 1761 .
PAN Z , ZHOU Y , LUO X , et al . Against NF- κ B/thymic stromal lymphopoietin signaling pathway, catechin alleviates the inflammation in allergic rhinitis [J]. Int Immunopharmacol , 2018 , 61 : 241 - 248 .
邓楠 , 杜欣 , 李长香 , 等 . 小青龙汤对变应性鼻炎小鼠树突状细胞的影响 [J]. 中南药学 , 2020 , 18 ( 3 ): 458 - 461 .
XU H , OHGAMI N , SAKASHITA M , et al . Intranasal levels of lead as an exacerbation factor for allergic rhinitis in humans and mice [J]. J Allergy Clin Immunol , 2021 , 148 ( 1 ): 139 - 147.e10 .
PAN Z , ZHOU Y , LUO X , et al . Against NF- κ B/thymic stromal lymphopoietin signaling pathway, catechin alleviates the inflammation in allergic rhinitis [J]. Int Immunopharmacol , 2018 , 61 : 241 - 248 .
叶茂宇 , 谭国林 . 变应性鼻炎小鼠造模方法研究进展 [J]. 中华耳鼻咽喉头颈外科杂志 , 2019 , 54 ( 9 ): 712 - 716 .
黄娟萍 , 罗裕 , 江力 , 等 . 中药药动学研究中给药剂量的现状分析 [J]. 中国药学杂志 , 2012 , 47 ( 21 ): 1685 - 1689 .
CHAN B , LAM C , TAM L S , et al . IL33: Roles in allergic inflammation and therapeutic perspectives [J]. Front Immunol , 2019 , 10 : 364 .
LIEW F Y , GIRARD J P , TURNQUIST H R . Interleukin-33 in health and disease [J]. Nat Rev Immunol , 2016 , 16 ( 11 ): 676 - 689 .
CHEN W Y , TSAI T H , YANG J L , et al . Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases [J]. Cell Physiol Biochem , 2018 , 49 ( 1 ): 349 - 358 .
MOLOFSKY A B , SAVAGE A K , LOCKSLEY R M . Interleukin-33 in tissue homeostasis, injury, and inflammation [J]. Immunity , 2015 , 42 ( 6 ): 1005 - 1019 .
LOTT J M , SUMPTER T L , TURNQUIST H R . New dog and new tricks: Evolving roles for IL-33 in type 2 immunity [J]. J Leukoc Biol , 2015 , 97 ( 6 ): 1037 - 1048 .
赖其廷 , 曾军 . 变应性鼻炎动物模型的研究进展 [J]. 国际呼吸杂志 , 2009 , 29 ( 17 ): 1086 - 1088 .
张永靖 . 变应性鼻炎动物模型的研究进展 [J]. 内蒙古医学杂志 , 2014 , 46 ( 6 ): 693 - 696 .
0
浏览量
25
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621